These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30842168)

  • 21. Protective effect of N-acetylcysteine on oxaliplatin-induced neurotoxicity in patients with colorectal and gastric cancers: A randomized, double blind, placebo-controlled, clinical trial.
    Bondad N; Boostani R; Barri A; Elyasi S; Allahyari A
    J Oncol Pharm Pract; 2020 Oct; 26(7):1575-1582. PubMed ID: 32063109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Oxaliplatin-induced peripheral neuropathy: how to create a barrier?].
    Taïb S; Durand J; Brunet I
    Med Sci (Paris); 2020 Oct; 36 Hors série n° 1():33-37. PubMed ID: 33052091
    [No Abstract]   [Full Text] [Related]  

  • 23. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: a pilot randomized clinical trial.
    Afonseca SO; Cruz FM; Cubero Dde I; Lera AT; Schindler F; Okawara M; Souza LF; Rodrigues NP; Giglio Ad
    Sao Paulo Med J; 2013; 131(1):35-8. PubMed ID: 23538593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
    Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
    BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.
    Vatandoust S; Joshi R; Pittman KB; Esterman A; Broadbridge V; Adams J; Singhal N; Yeend S; Price TJ
    Support Care Cancer; 2014 Feb; 22(2):513-8. PubMed ID: 24122404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial.
    Lemanska A; Harkin A; Iveson T; Kelly C; Saunders M; Faithfull S
    ESMO Open; 2023 Dec; 8(6):102063. PubMed ID: 37988949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
    Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
    J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
    Muto O; Ando H; Ono T; Itagaki H; Kobayashi Y; Onuki M; Akashi T; Tanaka Y; Hanaoka T
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):579-81. PubMed ID: 17431344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of Oxaliplatin-induced Chronic Neuropathy and Anticancer Efficacy Through Pharmacokinetic and Toxicodynamic Evaluation of a Rat Model of Colorectal Cancer.
    Ito Y; Kobuchi S; Takesada W; Takahashi C
    Anticancer Res; 2019 Aug; 39(8):4207-4213. PubMed ID: 31366507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial.
    Wang XS; Shi Q; Bhadkamkar NA; Cleeland CS; Garcia-Gonzalez A; Aguilar JR; Heijnen C; Eng C
    J Pain Symptom Manage; 2019 Oct; 58(4):662-671. PubMed ID: 31254639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients.
    Besora S; Santos C; Izquierdo C; Martinez-Villacampa MM; Bruna J; Velasco R
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1793-1801. PubMed ID: 29955956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve.
    Alberti P; Rossi E; Argyriou AA; Kalofonos HP; Briani C; Cacciavillani M; Campagnolo M; Bruna J; Velasco R; Cazzaniga ME; Cortinovis D; Valsecchi MG; Cavaletti G
    Support Care Cancer; 2018 Sep; 26(9):3143-3151. PubMed ID: 29594485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy.
    Kandula T; Farrar MA; Krishnan AV; Murray J; Timmins HC; Goldstein D; Lin CS; Kiernan MC; Park SB
    Muscle Nerve; 2018 Apr; 57(4):615-621. PubMed ID: 28881477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.
    Bruna J; Videla S; Argyriou AA; Velasco R; Villoria J; Santos C; Nadal C; Cavaletti G; Alberti P; Briani C; Kalofonos HP; Cortinovis D; Sust M; Vaqué A; Klein T; Plata-Salamán C
    Neurotherapeutics; 2018 Jan; 15(1):178-189. PubMed ID: 28924870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose Adjustment of Oxaliplatin Based on Renal Function in Patients With Metastatic Colorectal Cancer.
    Watanabe D; Fujii H; Matsuhashi N; Iihara H; Yamada Y; Ishihara T; Takahashi T; Yoshida K; Suzuki A
    Anticancer Res; 2020 Apr; 40(4):2379-2386. PubMed ID: 32234941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study.
    Oh PJ; Lee JR; Kim SK; Kim JH
    Eur J Oncol Nurs; 2020 Feb; 44():101676. PubMed ID: 31751847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.
    Velasco R; Bruna J; Briani C; Argyriou AA; Cavaletti G; Alberti P; Frigeni B; Cacciavillani M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):392-8. PubMed ID: 23813745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Survivors.
    Teng C; ; Blinman PL; Vardy JL
    J Natl Compr Canc Netw; 2022 Dec; 20(12):1308-1315. PubMed ID: 36509075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir.
    Coriat R; Alexandre J; Nicco C; Quinquis L; Benoit E; Chéreau C; Lemaréchal H; Mir O; Borderie D; Tréluyer JM; Weill B; Coste J; Goldwasser F; Batteux F
    J Clin Invest; 2014 Jan; 124(1):262-72. PubMed ID: 24355920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.